Oscar Health (OSCR) Financials

$15.03 +0.86 (+6.07%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$15.12 +0.09 (+0.57%)

As of 04:25 AM Eastern

Annual Income Statements for Oscar Health

This table shows Oscar Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	25	-271	-606	-573	-407	-261
Consolidated Net Income / (Loss)	26	-271	-610	-571	-407	-261
Net Income / (Loss) Continuing Operations	26	-271	-610	-571	-407	-261
Total Pre-Tax Income	33	-267	-610	-571	-406	-259
Total Operating Income	57	-236	-590	-544	-402	-259
Total Gross Profit	9,178	5,863	683	215	153	80
Total Revenue	9,178	5,863	3,964	1,839	463	488
Operating Revenue	9,178	5,863	3,964	1,839	463	488
Total Cost of Revenue	0.00	0.00	3,281	1,624	309	408
Total Operating Expenses	9,120	6,098	1,273	759	556	339
Selling, General & Admin Expense	1,756	1,426	1,257	265	167	111
Depreciation Expense	32	31	15	-	-	-
Other Operating Expenses / (Income)	7,333	4,642	-	494	389	229
Total Other Income / (Expense), net	-24	-32	-20	-26	-3.51	0.00
Interest Expense	24	25	23	25	3.51	-
Other Income / (Expense), net	-0.11	-7.08	2.42	-1.20	-	-
Income Tax Expense	7.31	3.29	-0.52	0.85	1.05	1.79
Net Income / (Loss) Attributable to Noncontrolling Interest	0.69	0.13	-3.28	1.18	0.00	0.00
Basic Earnings per Share	$0.11	($1.22)	($2.85)	($3.20)	($14.16)	($9.06)
Weighted Average Basic Shares Outstanding	240.39M	221.66M	212.48M	178.97M	29.26M	28.81M
Diluted Earnings per Share	$0.10	($1.22)	($2.85)	($3.20)	($14.16)	($9.06)
Weighted Average Diluted Shares Outstanding	265.85M	221.66M	212.48M	178.97M	29.26M	28.81M
Weighted Average Basic & Diluted Shares Outstanding	250.57M	229.73M	216.30M	210.40M	-	-

This table shows Oscar Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	275	-154	-55	56	177	-150	-65	-16	-40	-226	-193
Consolidated Net Income / (Loss)	276	-153	-54	56	177	-150	-66	-15	-40	-227	-194
Net Income / (Loss) Continuing Operations	276	-153	-54	56	177	-150	-66	-15	-40	-227	-194
Total Pre-Tax Income	288	-154	-52	61	178	-151	-65	-14	-38	-227	-195
Total Operating Income	297	-148	-48	68	186	-145	-58	-6.53	-25	-222	-192
Total Gross Profit	787	5,656	2,423	511	588	3,777	277	340	1,470	577	126
Total Revenue	3,046	2,392	2,423	2,219	2,142	1,432	1,440	1,522	1,470	995	978
Operating Revenue	3,046	2,392	2,423	2,219	2,142	1,432	1,440	1,522	1,470	995	978
Total Cost of Revenue	2,260	-3,263	0.00	1,709	1,555	-2,345	1,163	1,182	0.00	418	853
Operating Cost of Revenue	2,260	-	-	1,709	1,555	-	1,163	1,182	-	418	853
Total Operating Expenses	489	5,804	2,472	443	402	3,922	335	346	1,495	799	318
Selling, General & Admin Expense	483	466	460	435	394	364	326	337	399	1,023	79
Depreciation Expense	6.73	9.23	7.50	7.60	7.81	7.74	9.19	8.82	4.94	-	-
Total Other Income / (Expense), net	-8.91	-5.96	-3.94	-6.86	-7.08	-5.17	-6.54	-7.73	-12	-4.80	-2.79
Interest Expense	5.99	6.03	5.82	5.99	5.90	6.22	6.13	6.12	6.14	6.14	6.13
Other Income / (Expense), net	-2.92	0.07	1.88	-0.87	-1.18	1.05	-0.41	-1.61	-6.11	1.34	3.34
Income Tax Expense	13	-0.40	2.08	4.64	1.00	-0.81	0.92	1.16	2.02	-0.72	-1.62
Net Income / (Loss) Attributable to Noncontrolling Interest	0.24	0.26	0.21	0.11	0.11	0.19	-0.31	0.10	0.14	-0.51	-0.63
Basic Earnings per Share	$1.10	($0.68)	($0.22)	$0.24	$0.77	($0.68)	($0.29)	($0.07)	($0.18)	($1.05)	($0.91)
Weighted Average Basic Shares Outstanding	251.28M	240.39M	243.11M	238.67M	231.44M	221.66M	223.10M	219.40M	216.91M	212.48M	212.82M
Diluted Earnings per Share	$0.92	($0.50)	($0.22)	$0.20	$0.62	($0.68)	($0.29)	($0.07)	($0.18)	($1.05)	($0.91)
Weighted Average Diluted Shares Outstanding	305.94M	265.85M	243.11M	303.97M	293.80M	221.66M	223.10M	219.40M	216.91M	212.48M	212.82M
Weighted Average Basic & Diluted Shares Outstanding	254.68M	250.57M	247.27M	241.91M	237.22M	229.73M	226.11M	221.91M	218.35M	216.30M	214.76M

This table details how cash moves in and out of Oscar Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	-341	311	455	282	490	-17
Net Cash From Operating Activities	978	-272	380	-182	223	-165
Net Cash From Continuing Operating Activities	978	-272	380	-182	223	-165
Net Income / (Loss) Continuing Operations	26	-271	-610	-571	-407	-261
Consolidated Net Income / (Loss)	26	-271	-610	-571	-407	-261
Depreciation Expense	32	31	15	15	11	6.90
Amortization Expense	-26	-29	3.19	8.36	2.92	-6.65
Non-Cash Adjustments To Reconcile Net Income	416	-14	490	78	382	79
Changes in Operating Assets and Liabilities, net	530	10	482	289	233	17
Net Cash From Investing Activities	-1,387	577	-227	-775	-345	151
Net Cash From Continuing Investing Activities	-1,387	577	-227	-775	-345	151
Purchase of Property, Plant & Equipment	-28	-26	-29	-26	-14	-26
Purchase of Investments	-2,134	-837	-1,193	-1,810	-1,001	-878
Sale and/or Maturity of Investments	770	1,442	994	1,055	672	1,061
Other Investing Activities, net	3.93	-2.28	1.12	6.68	-1.24	-7.08
Net Cash From Financing Activities	68	6.45	301	1,239	612	-2.12
Net Cash From Continuing Financing Activities	68	6.45	301	1,239	612	-2.12
Repayment of Debt	0.00	0.00	-7.04	-166	-4.84	0.00
Issuance of Debt	0.00	0.00	305	0.00	147	-
Issuance of Common Equity	0.00	2.49	1.85	1,356	0.00	0.00
Other Financing Activities, net	68	3.96	1.30	59	94	0.87
Cash Interest Paid	34	23	10	4.26	0.00	0.00
Cash Income Taxes Paid	0.67	2.41	1.89	0.70	1.53	1.83

This table details how cash moves in and out of Oscar Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	709	319	-1,059	38	361	470	-922	212	551	-555	-249
Net Cash From Operating Activities	879	347	-500	497	634	297	-1,149	166	415	151	-548
Net Cash From Continuing Operating Activities	879	347	-500	497	634	297	-1,149	166	415	151	-548
Net Income / (Loss) Continuing Operations	276	-153	-54	56	177	-150	-66	-15	-40	-227	-194
Consolidated Net Income / (Loss)	276	-153	-54	56	177	-150	-66	-15	-40	-227	-194
Depreciation Expense	6.73	9.23	7.50	7.60	7.81	7.74	9.19	8.82	4.94	3.74	4.06
Amortization Expense	-7.48	-7.73	-6.54	-5.80	-6.03	-6.32	-7.39	-7.76	-7.13	-1.46	1.19
Non-Cash Adjustments To Reconcile Net Income	309	463	-596	399	151	370	-1,140	311	444	378	-505
Changes in Operating Assets and Liabilities, net	295	36	149	40	304	75	54	-131	12	-2.32	145
Net Cash From Investing Activities	-174	-31	-578	-478	-301	172	225	44	136	-707	299
Net Cash From Continuing Investing Activities	-174	-31	-578	-478	-301	172	225	44	136	-707	299
Purchase of Property, Plant & Equipment	-9.03	-6.82	-7.57	-7.56	-5.95	-6.10	-6.48	-5.62	-7.38	-7.13	-9.62
Purchase of Investments	-337	-110	-660	-806	-557	-215	-84	-335	-203	-850	-31
Sale and/or Maturity of Investments	172	86	87	335	261	396	316	385	346	150	339
Other Investing Activities, net	0.00	-0.01	2.49	0.83	0.63	-2.38	0.62	-0.52	0.00	-0.43	0.53
Net Cash From Financing Activities	4.87	3.82	19	19	27	1.07	2.32	2.55	0.51	0.53	0.42
Net Cash From Continuing Financing Activities	4.87	3.82	19	19	27	1.07	2.32	2.55	0.51	0.53	0.42
Other Financing Activities, net	4.87	3.82	19	19	27	1.07	0.30	2.55	0.04	0.01	0.37
Cash Interest Paid	0.15	11	11	0.15	11	0.26	0.26	11	11	0.27	0.26

This table presents Oscar Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	4,840	3,601	4,527	3,322	2,272
Total Current Assets	2,845	3,061	4,122	2,306	1,870
Cash & Equivalents	1,527	1,870	1,559	1,104	826
Short-Term Investments	624	690	1,397	587	368
Accounts Receivable	316	201	216	138	65
Other Current Assets	378	300	949	476	611
Plant, Property, & Equipment, net	67	62	60	47	36
Total Noncurrent Assets	1,929	478	345	969	366
Long-Term Investments	1,846	395	250	873	352
Other Noncurrent Operating Assets	82	83	95	97	13
Total Liabilities & Shareholders' Equity	4,840	3,601	4,527	3,322	2,272
Total Liabilities	3,824	2,795	3,634	1,929	1,823
Total Current Liabilities	3,463	2,429	3,264	1,852	1,666
Accounts Payable	432	273	298	235	138
Other Current Liabilities	3,031	2,156	2,966	1,618	1,528
Total Noncurrent Liabilities	361	366	370	77	157
Long-Term Debt	300	299	298	0.00	142
Other Noncurrent Operating Liabilities	61	68	72	77	15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,016	806	892	1,393	-1,296
Total Preferred & Common Equity	1,014	804	890	1,387	-1,296
Total Common Equity	1,014	804	890	1,387	-1,296
Common Stock	3,870	3,682	3,509	3,394	133
Retained Earnings	-2,851	-2,877	-2,606	-2,000	-1,427
Treasury Stock	-2.92	-2.92	-2.92	-2.92	-2.92
Accumulated Other Comprehensive Income / (Loss)	-1.83	1.31	-9.72	-3.67	0.88
Noncontrolling Interest	2.84	2.15	2.02	5.29	0.00

This table presents Oscar Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	5,844	4,483	5,006	4,419	3,350	4,565	4,483	4,309
Total Current Assets	3,775	2,368	3,359	3,504	2,992	4,193	4,131	3,931
Cash & Equivalents	2,237	1,206	2,268	2,231	1,400	2,322	2,110	2,113
Short-Term Investments	751	504	364	616	1,044	1,256	1,325	718
Accounts Receivable	489	301	398	343	207	193	186	215
Other Current Assets	298	357	329	314	340	422	511	885
Plant, Property, & Equipment, net	72	67	64	61	62	63	64	56
Total Noncurrent Assets	1,997	2,048	1,583	854	296	309	288	321
Long-Term Investments	1,904	1,964	1,496	766	207	217	193	224
Other Noncurrent Operating Assets	94	84	87	87	89	92	95	97
Total Liabilities & Shareholders' Equity	5,844	4,483	5,006	4,419	3,350	4,565	4,483	4,309
Total Liabilities	4,508	3,318	3,866	3,385	2,428	3,613	3,551	3,224
Total Current Liabilities	4,149	2,955	3,502	3,019	2,061	3,244	3,182	2,853
Accounts Payable	634	395	348	303	260	262	299	252
Other Current Liabilities	3,515	2,559	3,154	2,716	1,801	2,983	2,882	2,600
Total Noncurrent Liabilities	359	363	364	365	367	369	370	372
Long-Term Debt	300	299	299	299	299	298	298	298
Other Noncurrent Operating Liabilities	59	64	65	66	69	70	71	74
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,336	1,165	1,141	1,034	921	952	932	1,085
Total Preferred & Common Equity	1,333	1,163	1,138	1,032	919	950	930	1,082
Total Common Equity	1,333	1,163	1,138	1,032	919	950	930	1,082
Common Stock	3,902	3,837	3,787	3,737	3,654	3,621	3,583	3,479
Retained Earnings	-2,576	-2,698	-2,643	-2,699	-2,727	-2,661	-2,646	-2,380
Treasury Stock	-2.92	-2.92	-2.92	-2.92	-2.92	-2.92	-2.92	-2.92
Accumulated Other Comprehensive Income / (Loss)	9.60	26	-2.63	-2.59	-4.45	-6.86	-4.48	-14
Noncontrolling Interest	3.07	2.58	2.37	2.26	1.96	2.26	2.16	2.53

This table displays calculated financial ratios and metrics derived from Oscar Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	56.54%	47.92%	115.57%	297.30%	-5.20%	0.00%
EBITDA Growth	126.27%	57.71%	-8.85%	-34.70%	-49.75%	0.00%
EBIT Growth	123.55%	58.69%	-7.65%	-35.65%	-55.08%	0.00%
NOPAT Growth	127.13%	60.06%	-8.34%	-35.35%	-55.08%	0.00%
Net Income Growth	109.65%	55.61%	-6.67%	-40.46%	-55.76%	0.00%
EPS Growth	108.20%	57.19%	10.94%	77.40%	-56.29%	0.00%
Operating Cash Flow Growth	459.42%	-171.56%	309.28%	-181.60%	234.69%	0.00%
Free Cash Flow Firm Growth	365.18%	-176.50%	361.25%	-124.54%	0.00%	0.00%
Invested Capital Growth	-44.93%	8.21%	-72.13%	-22.59%	0.00%	0.00%
Revenue Q/Q Growth	11.69%	8.04%	14.40%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-4.74%	23.97%	-5.19%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-5.36%	24.02%	-4.22%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-7.26%	24.63%	-4.65%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-11.66%	22.09%	-4.96%	0.00%	0.00%	0.00%
EPS Q/Q Growth	225.00%	23.27%	-8.37%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	5.38%	34.83%	44.38%	-42.84%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	6.03%	28.23%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-21.39%	-29.29%	-20.52%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	17.23%	11.68%	33.16%	16.37%
EBITDA Margin	0.69%	-4.10%	-14.35%	-28.43%	-83.85%	-53.08%
Operating Margin	0.62%	-4.02%	-14.88%	-29.61%	-86.92%	-53.13%
EBIT Margin	0.62%	-4.14%	-14.82%	-29.68%	-86.92%	-53.13%
Profit (Net Income) Margin	0.28%	-4.62%	-15.38%	-31.08%	-87.91%	-53.50%
Tax Burden Percent	78.15%	101.23%	99.91%	100.15%	100.26%	100.69%
Interest Burden Percent	58.48%	110.14%	103.85%	104.56%	100.87%	100.00%
Effective Tax Rate	21.85%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	2.87%	-31.86%	-53.35%	-62.06%	-90.60%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	1.35%	-5.97%	-14.97%	-19.51%	-17.70%	0.00%
Return on Assets (ROA)	0.62%	-6.66%	-15.53%	-20.43%	-17.91%	0.00%
Return on Common Equity (ROCE)	2.86%	-31.78%	-53.18%	-3.08%	261.49%	0.00%
Return on Equity Simple (ROE_SIMPLE)	2.58%	-33.66%	-68.46%	-41.19%	31.39%	0.00%
Net Operating Profit after Tax (NOPAT)	45	-165	-413	-381	-282	-182
NOPAT Margin	0.49%	-2.81%	-10.42%	-20.73%	-60.84%	-37.19%
Net Nonoperating Expense Percent (NNEP)	-0.59%	-3.80%	-7.19%	-9.59%	-17.84%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	3.40%	-14.93%	-34.69%	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	82.77%	88.32%	66.84%	83.63%
SG&A Expenses to Revenue	19.13%	24.32%	31.72%	14.42%	36.01%	22.67%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	99.38%	104.02%	32.11%	41.29%	120.08%	69.51%
Earnings before Interest and Taxes (EBIT)	57	-243	-587	-546	-402	-259
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	63	-241	-569	-523	-388	-259
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	3.28	2.57	0.59	1.19	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.28	2.57	0.59	1.19	0.00	0.00
Price to Revenue (P/Rev)	0.36	0.35	0.13	0.89	3.12	2.96
Price to Earnings (P/E)	130.67	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.77%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	3.86	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	8.02	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	2.65	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.29	0.37	0.33	0.00	0.32	0.00
Long-Term Debt to Equity	0.29	0.37	0.33	0.00	0.32	0.00
Financial Leverage	-3.49	-3.28	-2.39	-2.15	-3.13	0.00
Leverage Ratio	4.63	4.79	3.43	3.04	5.06	0.00
Compound Leverage Factor	2.71	5.27	3.57	3.18	5.10	0.00
Debt to Total Capital	22.76%	27.04%	25.03%	0.00%	24.09%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	22.76%	27.04%	25.03%	0.00%	24.09%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.22%	0.19%	0.17%	0.38%	295.00%	0.00%
Common Equity to Total Capital	77.02%	72.76%	74.80%	99.62%	-219.08%	0.00%
Debt to EBITDA	4.74	-1.24	-0.52	0.00	-0.37	0.00
Net Debt to EBITDA	-58.51	11.04	5.11	0.00	3.62	0.00
Long-Term Debt to EBITDA	4.74	-1.24	-0.52	0.00	-0.37	0.00
Debt to NOPAT	6.69	-1.81	-0.72	0.00	-0.51	0.00
Net Debt to NOPAT	-82.64	16.11	7.04	0.00	4.99	0.00
Long-Term Debt to NOPAT	6.69	-1.81	-0.72	0.00	-0.51	0.00
Altman Z-Score	1.48	0.94	-0.04	-0.16	-0.68	0.00
Noncontrolling Interest Sharing Ratio	0.27%	0.25%	0.32%	95.04%	388.61%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.82	1.26	1.26	1.24	1.12	0.00
Quick Ratio	0.71	1.14	0.97	0.99	0.76	0.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	876	-330	432	-165	674	0.00
Operating Cash Flow to CapEx	3,506.45%	-1,064.08%	1,311.01%	-702.12%	1,588.56%	-636.14%
Free Cash Flow to Firm to Interest Expense	36.91	-13.43	19.09	-6.64	191.72	0.00
Operating Cash Flow to Interest Expense	41.21	-11.06	16.81	-7.30	63.38	0.00
Operating Cash Flow Less CapEx to Interest Expense	40.04	-12.10	15.53	-8.34	59.39	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	2.17	1.44	1.01	0.66	0.20	0.00
Accounts Receivable Turnover	35.49	28.07	22.34	18.05	7.08	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	142.59	96.26	74.44	44.62	12.92	0.00
Accounts Payable Turnover	0.00	0.00	12.32	8.72	2.25	0.00
Days Sales Outstanding (DSO)	10.28	13.00	16.34	20.22	51.52	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	29.63	41.84	162.26	0.00
Cash Conversion Cycle (CCC)	10.28	13.00	-13.29	-21.62	-110.74	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-2,682	-1,850	-2,016	-1,171	-955	0.00
Invested Capital Turnover	-4.05	-3.03	-2.49	-1.73	-0.97	0.00
Increase / (Decrease) in Invested Capital	-831	165	-845	-216	-955	0.00
Enterprise Value (EV)	-372	-585	-2,378	-914	1,785	0.00
Market Capitalization	3,323	2,069	528	1,645	1,445	1,445
Book Value per Share	$4.10	$3.56	$4.15	$6.62	($44.28)	$0.00
Tangible Book Value per Share	$4.10	$3.56	$4.15	$6.62	($44.28)	$0.00
Total Capital	1,316	1,105	1,190	1,393	592	0.00
Total Debt	300	299	298	0.00	142	0.00
Total Long-Term Debt	300	299	298	0.00	142	0.00
Net Debt	-3,698	-2,657	-2,908	-2,564	-1,404	0.00
Capital Expenditures (CapEx)	28	26	29	26	14	26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2,770	-1,928	-2,098	-1,237	-990	0.00
Debt-free Net Working Capital (DFNWC)	-618	632	858	454	205	0.00
Net Working Capital (NWC)	-618	632	858	454	205	0.00
Net Nonoperating Expense (NNE)	19	106	197	190	125	80
Net Nonoperating Obligations (NNO)	-3,698	-2,657	-2,908	-2,564	-1,404	0.00
Total Depreciation and Amortization (D&A)	6.05	2.10	18	23	14	0.25
Debt-free, Cash-free Net Working Capital to Revenue	-30.18%	-32.89%	-52.94%	-67.30%	-213.86%	0.00%
Debt-free Net Working Capital to Revenue	-6.73%	10.78%	21.64%	24.67%	44.26%	0.00%
Net Working Capital to Revenue	-6.73%	10.78%	21.64%	24.67%	44.26%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.11	($1.22)	($2.85)	($3.20)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	240.39M	221.66M	212.47M	178.97M	0.00	0.00
Adjusted Diluted Earnings per Share	$0.10	($1.22)	($2.85)	($3.20)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	265.85M	221.66M	212.47M	178.97M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	250.57M	229.73M	216.30M	210.40M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	45	-165	-413	-381	-282	-182
Normalized NOPAT Margin	0.49%	-2.81%	-10.42%	-20.73%	-60.84%	-37.19%
Pre Tax Income Margin	0.36%	-4.56%	-15.39%	-31.03%	-87.68%	-53.13%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	2.41	-9.86	-25.97	-21.92	-114.48	0.00
NOPAT to Interest Expense	1.89	-6.70	-18.25	-15.31	-80.13	0.00
EBIT Less CapEx to Interest Expense	1.23	-10.90	-27.25	-22.96	-118.47	0.00
NOPAT Less CapEx to Interest Expense	0.71	-7.74	-19.53	-16.35	-84.12	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-1.65%	0.00%	-1.15%

This table displays calculated financial ratios and metrics derived from Oscar Health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	42.20%	67.11%	68.30%	45.86%	45.77%	43.87%	47.17%	49.56%	51.08%	100.60%	120.38%
EBITDA Growth	57.64%	-2.20%	19.90%	1,071.36%	653.06%	34.66%	69.07%	92.96%	48.79%	-15.35%	10.60%
EBIT Growth	59.56%	-2.24%	20.73%	922.26%	685.87%	34.69%	68.97%	92.30%	56.04%	-12.68%	10.70%
NOPAT Growth	53.92%	-1.55%	16.95%	1,470.87%	1,139.24%	34.61%	69.72%	93.87%	62.99%	-13.36%	9.12%
Net Income Growth	55.23%	-2.30%	17.22%	465.07%	547.87%	33.86%	66.05%	86.24%	48.75%	-14.57%	8.48%
EPS Growth	48.39%	26.47%	24.14%	385.71%	444.44%	35.24%	68.13%	86.79%	50.00%	-26.51%	10.78%
Operating Cash Flow Growth	38.49%	16.83%	56.48%	200.35%	52.96%	96.09%	-109.58%	-22.82%	-26.32%	339.09%	6.94%
Free Cash Flow Firm Growth	1,754.00%	372.35%	363.62%	-56.33%	-88.69%	-138.79%	-150.54%	-76.31%	74.80%	0.00%	550.72%
Invested Capital Growth	-42.79%	-44.93%	-54.36%	-5.64%	4.86%	8.21%	14.44%	-23.06%	-34.80%	-72.13%	-70.76%
Revenue Q/Q Growth	27.33%	-1.28%	9.20%	3.60%	49.64%	-0.58%	-5.36%	3.53%	47.69%	1.71%	-3.82%
EBITDA Q/Q Growth	300.78%	-220.94%	-166.25%	-63.07%	230.17%	-151.54%	-703.36%	78.98%	84.62%	-19.09%	-82.71%
EBIT Q/Q Growth	299.24%	-217.58%	-169.46%	-63.69%	227.66%	-146.22%	-620.53%	74.13%	85.77%	-16.98%	-78.85%
NOPAT Q/Q Growth	374.65%	-205.39%	-154.05%	-66.05%	281.20%	-149.77%	-792.08%	74.26%	88.60%	-15.65%	-80.65%
Net Income Q/Q Growth	279.73%	-181.84%	-196.58%	-68.27%	218.45%	-128.05%	-325.95%	61.08%	82.51%	-17.06%	-72.62%
EPS Q/Q Growth	284.00%	-127.27%	-210.00%	-67.74%	191.18%	-134.48%	-314.29%	61.11%	82.86%	-15.38%	-71.70%
Operating Cash Flow Q/Q Growth	153.31%	169.34%	-200.60%	-21.63%	113.69%	125.83%	-794.32%	-60.09%	173.93%	127.61%	-355.69%
Free Cash Flow Firm Q/Q Growth	73.06%	-2.18%	260.90%	203.45%	125.42%	5.31%	-159.79%	-21.43%	-12.78%	23.38%	-71.98%
Invested Capital Q/Q Growth	-21.41%	-21.39%	17.81%	-17.88%	-23.22%	-29.29%	43.75%	-6.16%	-18.89%	-20.52%	19.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	25.82%	236.41%	100.00%	23.01%	27.43%	263.81%	19.22%	22.32%	100.00%	57.95%	12.85%
EBITDA Margin	9.63%	-6.11%	-1.88%	3.10%	8.69%	-9.99%	-3.95%	-0.47%	-2.29%	-21.99%	-18.78%
Operating Margin	9.75%	-6.17%	-2.00%	3.06%	8.66%	-10.16%	-4.04%	-0.43%	-1.73%	-22.36%	-19.66%
EBIT Margin	9.66%	-6.17%	-1.92%	3.02%	8.61%	-10.09%	-4.07%	-0.54%	-2.14%	-22.22%	-19.32%
Profit (Net Income) Margin	9.04%	-6.41%	-2.24%	2.54%	8.28%	-10.47%	-4.56%	-1.01%	-2.70%	-22.77%	-19.78%
Tax Burden Percent	95.59%	99.74%	103.97%	92.39%	99.44%	99.47%	101.41%	108.16%	105.37%	99.69%	99.17%
Interest Burden Percent	97.96%	104.08%	112.51%	91.05%	96.80%	104.30%	110.45%	175.18%	119.50%	102.77%	103.24%
Effective Tax Rate	4.41%	0.00%	0.00%	7.61%	0.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	10.47%	2.87%	2.83%	1.74%	-5.44%	-31.86%	-34.63%	-43.19%	-50.45%	-53.35%	-44.03%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	18.97%	-13.42%	-4.03%	4.56%	12.64%	-14.55%	-5.77%	-0.57%	-2.16%	-22.45%	-17.90%
Return on Assets (ROA)	17.77%	-13.93%	-4.71%	3.84%	12.16%	-15.10%	-6.47%	-1.08%	-2.72%	-23.00%	-18.33%
Return on Common Equity (ROCE)	10.45%	2.86%	2.83%	1.74%	-5.43%	-31.78%	-34.55%	-43.08%	-50.33%	-53.18%	-43.99%
Return on Equity Simple (ROE_SIMPLE)	9.31%	0.00%	2.54%	1.60%	-5.18%	0.00%	-37.77%	-50.03%	-61.52%	0.00%	-53.67%
Net Operating Profit after Tax (NOPAT)	284	-103	-34	63	185	-102	-41	-4.57	-18	-156	-135
NOPAT Margin	9.32%	-4.32%	-1.40%	2.82%	8.61%	-7.11%	-2.83%	-0.30%	-1.21%	-15.65%	-13.76%
Net Nonoperating Expense Percent (NNEP)	-0.22%	-1.57%	-0.72%	-0.17%	-0.21%	-1.73%	-0.98%	-0.32%	-0.68%	-2.59%	-2.23%
Return On Investment Capital (ROIC_SIMPLE)	17.36%	-7.86%	-	-	-	-9.22%	-	-	-	-13.08%	-
Cost of Revenue to Revenue	74.18%	-136.41%	0.00%	76.99%	72.57%	-163.81%	80.78%	77.68%	0.00%	42.05%	87.15%
SG&A Expenses to Revenue	15.85%	19.47%	19.00%	19.61%	18.40%	25.44%	22.63%	22.16%	27.12%	102.85%	8.03%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	16.07%	242.58%	102.00%	19.95%	18.76%	273.97%	23.27%	22.74%	101.73%	80.31%	32.51%
Earnings before Interest and Taxes (EBIT)	294	-148	-46	67	184	-144	-59	-8.14	-31	-221	-189
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	293	-146	-46	69	186	-143	-57	-7.08	-34	-219	-184
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.46	3.28	4.41	3.30	3.26	2.57	1.34	1.85	1.52	0.59	0.98
Price to Tangible Book Value (P/TBV)	2.46	3.28	4.41	3.30	3.26	2.57	1.34	1.85	1.52	0.59	0.98
Price to Revenue (P/Rev)	0.33	0.36	0.62	0.52	0.51	0.35	0.23	0.35	0.32	0.13	0.31
Price to Earnings (P/E)	26.63	130.67	177.24	206.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.75%	0.77%	0.56%	0.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.21	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	26.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	29.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	36.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	1.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	2.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.29	0.26	0.26	0.29	0.37	0.32	0.31	0.32	0.33	0.27
Long-Term Debt to Equity	0.22	0.29	0.26	0.26	0.29	0.37	0.32	0.31	0.32	0.33	0.27
Financial Leverage	-3.34	-3.49	-2.74	-3.50	-3.38	-3.28	-2.55	-3.10	-2.84	-2.39	-2.01
Leverage Ratio	4.33	4.63	3.75	4.57	4.53	4.79	3.82	4.23	3.90	3.43	2.84
Compound Leverage Factor	4.24	4.82	4.22	4.16	4.38	4.99	4.22	7.42	4.66	3.53	2.93
Debt to Total Capital	18.32%	22.76%	20.44%	20.78%	22.42%	27.04%	24.47%	23.86%	24.24%	25.03%	21.54%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	18.32%	22.76%	20.44%	20.78%	22.42%	27.04%	24.47%	23.86%	24.24%	25.03%	21.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.19%	0.22%	0.18%	0.16%	0.17%	0.19%	0.16%	0.18%	0.18%	0.17%	0.18%
Common Equity to Total Capital	81.49%	77.02%	79.39%	79.06%	77.41%	72.76%	75.37%	75.95%	75.58%	74.80%	78.27%
Debt to EBITDA	1.76	4.74	4.51	5.44	-14.39	-1.24	-0.94	-0.67	-0.56	-0.52	-0.55
Net Debt to EBITDA	-26.93	-58.51	-50.86	-69.56	159.50	11.04	7.43	7.89	6.20	5.11	5.10
Long-Term Debt to EBITDA	1.76	4.74	4.51	5.44	-14.39	-1.24	-0.94	-0.67	-0.56	-0.52	-0.55
Debt to NOPAT	2.05	6.69	6.20	7.92	-17.30	-1.81	-1.36	-0.95	-0.78	-0.72	-0.75
Net Debt to NOPAT	-31.36	-82.64	-69.93	-101.37	191.76	16.11	10.75	11.18	8.70	7.04	6.99
Long-Term Debt to NOPAT	2.05	6.69	6.20	7.92	-17.30	-1.81	-1.36	-0.95	-0.78	-0.72	-0.75
Altman Z-Score	1.63	1.34	1.73	1.30	1.49	1.03	1.06	0.81	0.64	0.22	0.38
Noncontrolling Interest Sharing Ratio	0.23%	0.27%	0.22%	0.22%	0.23%	0.25%	0.22%	0.25%	0.23%	0.32%	0.10%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.91	0.82	0.80	0.96	1.16	1.26	1.45	1.29	1.30	1.26	1.38
Quick Ratio	0.84	0.71	0.68	0.87	1.06	1.14	1.29	1.16	1.14	0.97	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,260	728	744	206	68	-267	-282	472	601	689	558
Operating Cash Flow to CapEx	9,733.46%	5,086.08%	-6,610.38%	6,574.33%	10,661.56%	4,865.09%	-17,738.32%	2,946.84%	5,620.21%	2,123.34%	-5,702.00%
Free Cash Flow to Firm to Interest Expense	210.17	120.80	127.97	34.42	11.51	-42.99	-46.05	77.15	97.94	112.31	91.17
Operating Cash Flow to Interest Expense	146.57	57.55	-86.01	82.98	107.48	47.75	-187.48	27.05	67.59	24.68	-89.51
Operating Cash Flow Less CapEx to Interest Expense	145.06	56.42	-87.31	81.72	106.47	46.77	-188.54	26.13	66.38	23.51	-91.08
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.96	2.17	2.10	1.51	1.47	1.44	1.42	1.07	1.01	1.01	0.93
Accounts Receivable Turnover	24.24	35.49	32.37	24.46	24.71	28.07	25.68	27.03	25.98	22.34	20.81
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	151.14	142.59	127.74	113.90	104.16	96.26	91.57	87.11	79.17	74.44	69.38
Accounts Payable Turnover	1.50	0.00	16.96	22.08	20.56	0.00	10.79	10.06	8.90	12.32	15.76
Days Sales Outstanding (DSO)	15.06	10.28	11.28	14.92	14.77	13.00	14.21	13.50	14.05	16.34	17.54
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	242.66	0.00	21.52	16.53	17.75	0.00	33.84	36.29	41.01	29.63	23.15
Cash Conversion Cycle (CCC)	-227.61	10.28	-10.24	-1.61	-2.98	13.00	-19.63	-22.79	-26.96	-13.29	-5.61
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3,256	-2,682	-2,209	-2,688	-2,280	-1,850	-1,431	-2,544	-2,397	-2,016	-1,673
Invested Capital Turnover	-3.64	-4.05	-4.51	-2.76	-2.79	-3.03	-3.50	-2.15	-2.14	-2.49	-2.61
Increase / (Decrease) in Invested Capital	-976	-831	-778	-144	117	165	242	-477	-619	-845	-693
Enterprise Value (EV)	-1,304	-372	1,759	-73	50	-585	-1,115	-1,734	-1,912	-2,378	-1,696
Market Capitalization	3,285	3,323	5,131	3,753	3,362	2,069	1,236	1,760	1,415	528	1,059
Book Value per Share	$5.32	$4.10	$4.81	$4.80	$4.46	$3.56	$4.14	$4.35	$4.30	$4.15	$5.10
Tangible Book Value per Share	$5.32	$4.10	$4.81	$4.80	$4.46	$3.56	$4.14	$4.35	$4.30	$4.15	$5.10
Total Capital	1,636	1,316	1,465	1,440	1,333	1,105	1,220	1,250	1,230	1,190	1,382
Total Debt	300	300	299	299	299	299	299	298	298	298	298
Total Long-Term Debt	300	300	299	299	299	299	299	298	298	298	298
Net Debt	-4,592	-3,698	-3,375	-3,828	-3,314	-2,657	-2,353	-3,496	-3,328	-2,908	-2,757
Capital Expenditures (CapEx)	9.03	6.82	7.57	7.56	5.95	6.10	6.48	5.62	7.38	7.13	9.62
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3,362	-2,770	-2,297	-2,774	-2,363	-1,928	-1,513	-2,629	-2,485	-2,098	-1,753
Debt-free Net Working Capital (DFNWC)	-374	-618	-587	-143	484	632	931	948	950	858	1,079
Net Working Capital (NWC)	-374	-618	-587	-143	484	632	931	948	950	858	1,079
Net Nonoperating Expense (NNE)	8.52	50	21	6.34	7.04	48	25	11	22	71	59
Net Nonoperating Obligations (NNO)	-4,592	-3,698	-3,375	-3,828	-3,314	-2,657	-2,353	-3,496	-3,328	-2,908	-2,757
Total Depreciation and Amortization (D&A)	-0.75	1.51	0.96	1.80	1.78	1.42	1.80	1.06	-2.19	2.27	5.25
Debt-free, Cash-free Net Working Capital to Revenue	-33.35%	-30.18%	-27.95%	-38.36%	-36.15%	-32.89%	-27.89%	-52.96%	-55.70%	-52.94%	-50.58%
Debt-free Net Working Capital to Revenue	-3.71%	-6.73%	-7.14%	-1.97%	7.41%	10.78%	17.15%	19.10%	21.29%	21.64%	31.13%
Net Working Capital to Revenue	-3.71%	-6.73%	-7.14%	-1.97%	7.41%	10.78%	17.15%	19.10%	21.29%	21.64%	31.13%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.10	($0.68)	($0.22)	$0.24	$0.77	($0.68)	($0.29)	($0.07)	($0.18)	($1.05)	($0.91)
Adjusted Weighted Average Basic Shares Outstanding	251.28M	240.39M	243.11M	238.67M	231.44M	221.66M	223.10M	219.40M	216.91M	212.48M	212.82M
Adjusted Diluted Earnings per Share	$0.92	($0.50)	($0.22)	$0.20	$0.62	($0.68)	($0.29)	($0.07)	($0.18)	($1.05)	($0.91)
Adjusted Weighted Average Diluted Shares Outstanding	305.94M	265.85M	243.11M	303.97M	293.80M	221.66M	223.10M	219.40M	216.91M	212.48M	212.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	254.68M	250.57M	247.27M	241.91M	237.22M	229.73M	226.11M	221.91M	218.35M	216.30M	214.76M
Normalized Net Operating Profit after Tax (NOPAT)	284	-103	-34	63	185	-102	-41	-4.57	-18	-156	-135
Normalized NOPAT Margin	9.32%	-4.32%	-1.40%	2.82%	8.61%	-7.11%	-2.83%	-0.30%	-1.21%	-15.65%	-13.76%
Pre Tax Income Margin	9.46%	-6.42%	-2.16%	2.75%	8.33%	-10.52%	-4.50%	-0.94%	-2.56%	-22.84%	-19.95%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	49.08	-24.50	-8.00	11.17	31.24	-23.23	-9.57	-1.33	-5.13	-36.05	-30.86
NOPAT to Interest Expense	47.38	-17.16	-5.82	10.46	31.26	-16.38	-6.65	-0.75	-2.89	-25.38	-21.98
EBIT Less CapEx to Interest Expense	47.58	-25.64	-9.30	9.91	30.23	-24.21	-10.63	-2.25	-6.33	-37.21	-32.43
NOPAT Less CapEx to Interest Expense	45.88	-18.29	-7.12	9.20	30.26	-17.36	-7.71	-1.66	-4.10	-26.55	-23.55
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Oscar Health's Financials

When does Oscar Health's financial year end?

According to the most recent income statement we have on file, Oscar Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Oscar Health's net income changed over the last 5 years?

Oscar Health's net income appears to be on a downward trend, with a most recent value of $26.12 million in 2024, falling from -$261.18 million in 2019. The previous period was -$270.59 million in 2023. Find out what analysts predict for Oscar Health in the coming months.

What is Oscar Health's operating income?

Oscar Health's total operating income in 2024 was $57.27 million, based on the following breakdown:

Total Gross Profit: $9.18 billion
Total Operating Expenses: $9.12 billion

How has Oscar Health revenue changed over the last 5 years?

Over the last 5 years, Oscar Health's total revenue changed from $488.19 million in 2019 to $9.18 billion in 2024, a change of 1,779.9%.

How much debt does Oscar Health have?

Oscar Health's total liabilities were at $3.82 billion at the end of 2024, a 36.8% increase from 2023, and a 109.8% increase since 2020.

How much cash does Oscar Health have?

In the past 4 years, Oscar Health's cash and equivalents has ranged from $826.33 million in 2020 to $1.87 billion in 2023, and is currently $1.53 billion as of their latest financial filing in 2024.

How has Oscar Health's book value per share changed over the last 5 years?

Over the last 5 years, Oscar Health's book value per share changed from 0.00 in 2019 to 4.10 in 2024, a change of 409.9%.

Related Companies

This page (NYSE:OSCR) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oscar Health (OSCR) Financials

Frequently Asked Questions About Oscar Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oscar Health (OSCR) Financials

Annual Income Statements for Oscar Health

Quarterly Income Statements for Oscar Health

Annual Cash Flow Statements for Oscar Health

Quarterly Cash Flow Statements for Oscar Health

Annual Balance Sheets for Oscar Health

Quarterly Balance Sheets for Oscar Health

Annual Metrics And Ratios for Oscar Health

Quarterly Metrics And Ratios for Oscar Health

Frequently Asked Questions About Oscar Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools